Introduction
Vaccination against human papillomavirus (HPV) is recommended to prevent HPV infections and HPV-associated diseases, including cancers. Routine vaccination at age 11 or 12 years has been recommended by the Advisory Committee on Immunization Practices (ACIP) since 2006 for females and since 2011 for males (1, 2) . This report provides recommendations and guidance regarding use of HPV vaccines and updates ACIP HPV vaccination recommendations previously published in 2014 and 2015 (1, 2) . This report includes new recommendations for use of a 2-dose schedule for girls and boys who initiate the vaccination series at ages 9 through 14 years. Three doses remain recommended for persons who initiate the vaccination series at ages 15 through 26 years and for immunocompromised persons.
Background
HPV infection causes cervical, vaginal, and vulvar cancers in women; penile cancers in men; and oropharyngeal and anal cancers as well as genital warts in both men and women (3) . Three HPV vaccines are licensed for use in the United States. All are noninfectious. Quadrivalent and 9-valent HPV vaccines (4vHPV and 9vHPV, Gardasil and Gardasil 9, Merck and Co, Inc., Whitehouse Station, New Jersey) are licensed for use in females and males aged 9 through 26 years (1). Bivalent HPV vaccine (2vHPV, Cervarix, GlaxoSmithKline, Rixensart, Belgium) is licensed for use in females aged 9 through 25 years (1). As of late 2016, only 9vHPV is being distributed in the United States. The majority of all HPV-associated cancers are caused by HPV 16 or 18, types targeted by all three vaccines. In addition, 4vHPV targets HPV 6 and 11, types that cause genital warts. 9vHPV protects against these and five additional types: HPV 31, 33, 45, 52, and 58. All three vaccines have been approved for administration in a 3-dose series at intervals of 0, 1 or 2, and 6 months. In October 2016, after considering new clinical trial results (4), the Food and Drug Administration (FDA) also approved 9vHPV for use in a 2-dose series for girls and boys aged 9 through 14 years (5). In October 2016, ACIP recommended a 2-dose schedule for adolescents initiating HPV vaccination in this age range. This report provides recommendations for use of 2-dose and 3-dose schedules for HPV vaccination.
Methods
During November 2015-October 2016, the ACIP HPV Vaccines Work Group held monthly telephone conferences to 1) review and evaluate the quality of the evidence assessing immunogenicity, efficacy, and postlicensure effectiveness of a 2-dose schedule; 2) consider benefits and harms of a 2-dose schedule; 3) weigh the variability in the values and preferences of patients and providers for a 2-dose schedule; and 4) examine health economic analyses. During teleconferences, summaries of findings were presented for Work Group discussion. health outcomes related to HPV vaccination after 2 doses of 9vHPV, 4vHPV, or 2vHPV, administered at an interval of 0 and ≥6 months (±4 weeks) to persons aged 9 through 14 years. The review focused on this age group given available 2-dose trial data for 9vHPV (4) .
Immunogenicity outcomes of interest were seroconversion, geometric mean titers (GMTs), or antibody avidity. Studies were excluded if they lacked a comparison group in which efficacy of 3 doses of HPV vaccine against clinical endpoints was demonstrated in clinical trials (e.g., females aged 15 through 26 years). Evidence regarding a 3-dose schedule for HPV vaccine was reviewed previously (1,2).
Quality of evidence was evaluated using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach.
Detailed methods and GRADE tables can be found online (6). Other studies from the search and from the broader literature informed additional expert guidance that extended beyond the research question addressed formally via GRADE analysis (7). Evidence was reviewed by the Work Group, summarized, and publicly presented at the February and June 2016 ACIP meetings. CDC vaccine recommendations are developed using the GRADE framework (8) . Proposed recommendations were presented, and after a public comment period, were approved unanimously by the voting ACIP members at the October 2016 ACIP meeting.
Summary of Key Findings
Immunogenicity. In the 9vHPV clinical trial that was the basis for FDA approval of a 2-dose series, participants were girls and boys aged 9 through 14 years, compared with young females aged 16 through 26 years (4). Among 1,377 participants, ≥97.9% seroconverted to all nine vaccine-preventable HPV types by 4 weeks after the last dose. For girls and boys who received 2 doses of 9vHPV 6 months apart (0, 6 month schedule) or 12 months apart (0, 12 month schedule), noninferiority criteria were met for seroconversion and GMTs. Furthermore, GMTs were significantly higher for all 9vHPV types among persons aged 9 through 14 years who received 2 doses compared with females aged 16-26 years who received 3 doses (0, 2, 6 month schedule). Six additional studies found similar results for 4vHPV and 2vHPV (6).
Immunogenicity was found to be noninferior with 2 doses in persons aged 9 through 14 years compared with 3 doses in a group in which clinical efficacy was demonstrated (GRADE evidence type 3).
Efficacy and effectiveness. Although efficacy and postlicensure effectiveness studies were reviewed, none met the inclusion criteria detailed above. The prelicensure HPV vaccine efficacy trials were conducted with 3-dose series; post hoc analyses conducted with data from some of these trials found high efficacy against infection among vaccinees who received 2 doses and those who received 3 doses (9,10). A large study comparing 2 doses with 3 doses also suggested similar efficacy against infection (11) . Postlicensure effectiveness studies have found lower effectiveness against various HPV-associated outcomes among vaccinees who received 2 doses compared with those who received 3 doses, but methodologic challenges with these studies limit interpretation of the findings. ** Duration of protection. Through 10 years of follow-up from clinical trials, no evidence of waning protection after a 3-dose series of HPV vaccine has been found (1). Because antibody kinetics are similar with 2-dose and 3-dose series, duration of protection is also expected to be long-lasting after a 2-dose series (12, 13) .
Health impact and cost-effectiveness modeling. Population-level effectiveness and cost-effectiveness of 2-dose and 3-dose schedules of 9vHPV in the United States have been modeled (14) . Assuming both efficacy and duration of protection are similar with either schedule, a 2-dose series would be cost-saving and have similar population impact to a 3-dose series. Even if duration of protection is 20 years for a 2-dose series and lifelong for a 3-dose series, additional benefits of a 3-dose series would be relatively small, and a 2-dose series would be more cost-effective (14) .
Rationale HPV vaccines are highly effective and safe, and a powerful prevention tool for reducing HPV infections and HPV-associated cancers (1,2).
Based on the available immunogenicity evidence, a 2-dose schedule (0, 6-12 months) will have efficacy equivalent to a 3-dose schedule (0, 1-2, 6 months) if the HPV vaccination series is initiated before the 15th birthday (GRADE evidence type 3) (6). ACIP recommends a 2-dose schedule for HPV vaccination of girls and boys who initiate the vaccination series at ages 9 through 14 years (Category A recommendation).
Recommendations
Routine and catch-up age groups. ACIP recommends routine HPV vaccination at age 11 or 12 years. Vaccination can be given starting at age 9 years. ACIP also recommends vaccination for females through age 26 years and for males through age 21 years who were not adequately vaccinated previously. (Table) .
For persons initiating vaccination on or after their 15th birthday, the recommended immunization schedule is 3 doses of HPV vaccine. The second dose should be administered 1-2 months after the first dose, and the third dose should be administered 6 months after the first dose (0, 1-2, 6 month schedule) (Table) .
Persons vaccinated previously. Persons who initiated vaccination with 9vHPV, 4vHPV, or 2vHPV before their 15th birthday, and received 2 doses of any HPV vaccine at the recommended dosing schedule (0, 6-12 months), or 3 doses of any HPV vaccine at the recommended dosing schedule (0, 1-2, 6 months), are considered adequately vaccinated.
Persons who initiated vaccination with 9vHPV, 4vHPV, or 2vHPV on or after their 15th birthday, and received 3 doses of any HPV vaccine at the recommended dosing schedule, are considered adequately vaccinated.
9vHPV may be used to continue or complete a vaccination series started with 4vHPV or 2vHPV.
For persons who have been adequately vaccinated with 2vHPV or 4vHPV, there is no ACIP recommendation regarding additional vaccination with 9vHPV.
Interrupted schedules. If the vaccination schedule is interrupted, the series does not need to be restarted. The number of recommended doses is based on age at administration of the first dose.
Special populations. For children with a history of sexual abuse or assault, ACIP recommends routine HPV vaccination beginning at age 9 years.
For men who have sex with men, ACIP recommends routine HPV vaccination as for all males, and vaccination through age 26 years for those who were not adequately vaccinated previously.
For transgender persons, ACIP recommends routine HPV vaccination as for all adolescents, and vaccination through age 26 years for those who were not adequately vaccinated previously.
Medical conditions. ACIP recommends vaccination with 3 doses of HPV vaccine (0, 1-2, 6 months) for females and males aged 9 through 26 years with primary or secondary immunocompromising conditions that might reduce cell-mediated or humoral immunity, *** such as B lymphocyte antibody deficiencies, T lymphocyte complete or partial defects, HIV infection, malignant neoplasms, transplantation, autoimmune disease, or immunosuppressive therapy, because immune response to vaccination might be attenuated (Table) (7).
Contraindications and precautions. Contraindications and precautions, including those related to pregnancy, are unchanged from previous recommendations (1, 2) . Adverse events occurring after administration of any vaccine should be reported to the Vaccine Adverse Event
Reporting System (VAERS). Reports can be submitted to VAERS online, by fax, or by mail. Additional information about VAERS is available by telephone (1-800-822-7967) or online (https://vaers.hhs.gov (https://vaers.hhs.gov) ).
exposure.
In a 2-dose schedule of HPV vaccine, the minimum interval between the first and second doses is 5 months. If the second dose is administered after a shorter interval, a third dose should be administered a minimum of 12 weeks after the second dose and a minimum of 5 months after the first dose.
In a 3-dose schedule of HPV vaccine, the minimum intervals are 4 weeks between the first and second doses, 12 weeks between the second and third doses, and 5 months between the first and third doses. If a vaccine dose is administered after a shorter interval, it should be readministered after another minimum interval has elapsed since the most recent dose.
Including men who identify as gay or bisexual, or who intend to have sex with men.
*** The recommendation for a 3-dose schedule of HPV vaccine does not apply to children aged <15 years with asplenia, asthma, chronic granulomatous disease, chronic liver disease, chronic lung disease, chronic renal disease, central nervous system anatomic barrier defects (e.g., cochlear implant), complement deficiency, diabetes, heart disease, or sickle cell disease. Persons initiating HPV vaccination at ages 15 through 26 years and immunocompromised persons initiating HPV vaccination at ages 9 through 26 years 3 0, 1-2, 6 months** *ACIP recommends routine HPV vaccination for adolescents at age 11 or 12 years; vaccination may be given starting at age 9 years.
CDC. Grading of Recommendations
Persons with primary or secondary immunocompromising conditions that might reduce cell-mediated or humoral immunity (see also:
Medical conditions)
In a 2-dose schedule of HPV vaccine, the minimum interval between the first and second doses is 5 months.
For persons who were not adequately vaccinated previously, ACIP recommends vaccination for females through age 26 years and for 
